Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 10, 2026 2 hours ago
Medical News: A newly published clinical study has identified a promising oral supplement that may significantly accelerate the body’s ability to clear human papillomavirus (HPV), a widespread viral infection and the leading cause of cervical cancer. The findings provide new insight into a potential supportive approach for women who are currently managed through routine monitoring rather than active treatment.
Clinical study links oral supplement to faster HPV clearance and improved cervical cell recovery
Persistent HPV Infection and Its Risks
HPV is one of the most common sexually transmitted infections globally, with certain high-risk strains responsible for the majority of cervical cancer cases. Although most infections resolve naturally within one to two years, persistent infections can trigger abnormal cellular changes in the cervix, increasing the risk of progression to cancer.
For many women, particularly those with mild or no symptoms, clinical management often involves repeated testing over extended periods. While this approach is medically appropriate, it can lead to prolonged uncertainty and psychological stress, highlighting the need for supportive interventions that may enhance viral clearance.
Study Design and Clinical Setting
The study evaluated 239 women with confirmed HPV infection who were monitored at a tertiary care center between 2023 and 2025. Participants were divided into two groups: one group of 119 women received the oral supplement Papivir/Pavirona® twice daily for six months, while a control group of 120 women underwent standard clinical follow-up without additional intervention.
Researchers assessed HPV DNA status and cervical cytology at baseline, six months, and twelve months. Both groups were comparable at the start of the study in terms of age, HPV genotype distribution, and initial cervical findings, allowing for a balanced and reliable comparison of outcomes.
This
Medical News report highlights that the study was conducted in a real-world clinical environment, reflecting routine patient care rather than controlled experimental conditions.
Significant Improvements in Viral Clearance
The results demonstrated a substantial improvement in HPV clearance among women who received the supplement. At six months, 76.5 percent of participants in the treatment group achieved overall HPV clearance, compared to 47.5 percent in the control group.
Complete clearance rates were particularly notable, with 65.5 percent of supplement users testing negative for HPV at six months, compared to only 29.2 percent in those receiving standard care. These improvements were observed across multiple HPV genotypes, including high-risk strains such as HPV 16 and HPV 18.
At the twelve-month follow-up, the benefits remained consistent. Approximately 69.1 percent of women in the supplement group achieved complete clearance, compared to 46.0 percent in the control group. The data presented in the study tables clearly show that
the supplement group maintained a significant advantage in viral elimination over time.
Enhanced Recovery of Cervical Cell Abnormalities
Beyond viral clearance, the study also examined changes in cervical cytology, which reflect the health of cervical cells and the risk of disease progression. Women receiving Papivir/Pavirona® experienced higher rates of cytological regression, indicating improvement or normalization of abnormal cell findings.
At six months, 83.8 percent of women in the treatment group showed regression of cervical abnormalities, compared to 70.0 percent in the control group. By twelve months, complete regression was observed in 77.9 percent of supplement users, significantly higher than the 52.8 percent observed in the control group.
These findings suggest that the supplement may contribute not only to eliminating the virus but also to reversing early cellular changes associated with HPV infection.
Biological Mechanisms Behind the Supplement
Papivir/Pavirona® is a multi-component oral formulation containing quercetin, green tea extract, selenium, cinnamon extract, and licorice root extract. These compounds have been widely studied for their antiviral, antioxidant, and anti-inflammatory properties.
The study suggests that these ingredients may act synergistically to disrupt viral persistence, reduce oxidative stress, and support immune responses. Some components have also been shown in experimental models to influence cellular pathways involved in HPV-related disease progression, including mechanisms linked to inflammation and abnormal cell growth.
Research Institutions Involved
The study was conducted by researchers from:
-Department of Obstetrics and Gynecology, Hacettepe University, Ankara, Türkiye
-Division of Gynecologic Oncology, Hacettepe University, Ankara, Türkiye
-Sincan Training and Research Hospital, Ankara, Türkiye
Safety and Clinical Implications
The supplement was generally well tolerated throughout the study period. Only one participant reported a mild skin rash, which resolved without discontinuation. No serious adverse effects were documented, suggesting a favorable safety profile.
Given its non-invasive nature, the supplement may offer a practical option for women undergoing long-term monitoring, particularly those seeking additional support during the natural course of infection.
Conclusion
The findings of this study indicate that Papivir/Pavirona® supplementation is associated with significantly improved HPV clearance rates and enhanced regression of cervical cell abnormalities compared to standard follow-up alone.
The consistency of these benefits across different HPV genotypes and clinical presentations suggests a broad potential role for this formulation as a supportive intervention. However, as the study was retrospective and conducted at a single center, the results should be interpreted with caution. Larger, well-designed randomized controlled trials are necessary to confirm these findings, evaluate long-term outcomes, and determine optimal patient selection. Despite these limitations, the study provides compelling preliminary evidence that targeted oral supplementation may help address a significant unmet need in HPV management.
The study findings were published in the peer reviewed journal: Viruses.
https://www.mdpi.com/1999-4915/18/4/455
For the latest HPV research, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/stds
https://www.thailandmedical.news/articles/herbs-and-phytochemicals
Share
Tweet
Share
